Corvus Pharmaceuticals, Inc. Proceeds from Sale of Available-for-sale Securities
Corvus Pharmaceuticals, Inc. (CRVS) reported Proceeds from Sale of Available-for-sale Securities of $4.20 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecurities · last filed 2018-03-01
- Corvus Pharmaceuticals, Inc. proceeds from sale of available-for-sale securities for fiscal 2016 was $4.20M.
| Period end | Proceeds from Sale of Available-for-sale Securities 12 month |
|---|---|
| 2016-12-31 | $4.20M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |